Members

Network members

Dr Afrodita Marcu

Research Fellow
School of Health Sciences, University of Surrey
afrodita.marcu@surrey.ac.uk

Full Bio

I am a social psychologist by background and have expertise in researching patient experience of symptoms, help-seeking, illness, and diagnosis. My research interests are in the areas of risk perception, risk communication, lived experience of disease, cancer early diagnosis, and promotion of early presentation with symptoms suggestive of cancer. I am interested in researching how patients make sense of their symptoms and seek medical help prior to receiving a mesothelioma diagnosis. I have recently worked on a project funded by the June Hancock Mesothelioma Research Fund which has focused on developing sustainable patient and public involvement (PPI) in mesothelioma research. I am looking for research collaborations that address or include psycho-social aspects of mesothelioma, e.g. patient experience of help-seeking for symptoms later diagnosed as mesothelioma; psychological adjustment to a diagnosis of mesothelioma; facilitating patient and carer involvement in mesothelioma research.

Visit Profile

Prof Alexandre Xavier Falcão

Laboratory of Image Data Science (LIDS), Institute of Computing (IC)
University of Campinas (UNICAMP)
afalcao@ic.unicamp.br

Full Bio

Our group develops image processing, visualization, and analysis techniques to address data science problems from different areas, such as Medicine, Geology, and Agriculture. The group has investigated and developed interactive machine learning methods for data annotation and design of explainable convolutional neural networks with minimum user effort. Lung cancer, particularly Mesothelioma, is a topic of high interest, in which the group has experience with abnormal lung segmentation, pleural plaque detection, and nodule detection in CT images of the thorax.

Visit Profile

Dr Alexandrea MacPherson

PREDICT-Meso Project Manager
University of Glasgow
Alexandrea.MacPherson@glasgow.ac.uk

Full Bio
Dr MacPherson graduated with a PhD in Immunology in 2012 before moving on to Research Manager and Project Co-ordinator roles at NHS GGC, University of Glasgow, and Oregon Health and Science University. Dr MacPherson is responsible for overall project management of the PREDICT-Meso Network, co-ordination of the work packages and ensuring the PREDICT-Meso aims are met.

Dr MacPherson is the lead contact for the Network and the clinical study Meso-ORIGINS, which she co-ordinates.

Dr Alina Ionescu

Consultant respiratory physician
Royal Gwent Hospital
Alina.Ionescu2@wales.nhs.uk

Full Bio

Meso-ORIGINS study site PI for Aneurin Bevan University Health Board.
Respiratory consultant, member of the lung cancer and mesothelioma MDT, local pleural lead, running with the pleural team the ambulatory pleural service and thoracoscopy service, co-founder with the local mesothelioma nurse of the mesothelioma and lung cancer patient support group. PI to a number of research trials, over 70 papers, book chapters and abstracts published.

Professor Andrew Biankin

Co-Investigator WP2
Director of Translational Research Centre
University of Glasgow
Andrew.Biankin@glasgow.ac.uk

Full Bio

Professor Biankin is a surgeon-scientist and Director of the Wolfson Wohl Cancer Research Centre at the University of Glasgow, where he established the Glasgow Precision Oncology Laboratory in 2016. Professor Biankin is also Chair of the UK-wide Precision-Panc programme of clinical trials for patients with pancreatic cancer. Professor Biankin is the Executive Director of the International Cancer Genome Consortium, Accelerating Research in Genomic Oncology (ICGC ARGO) project.
www.gpol.org

Dr Andrew Griffiths

Consultant Respiratory Physician
Aneurin Bevan University Health Board
andrew.griffiths3@wales.nhs.uk

Full Bio
Meso-ORIGINS Study Site Co-investigator for Aneurin Bevan University Health Board

Dr Anna Bibby

Co-Investigator & Co-Lead WP5.2
Respiratory Consultant & NIHR Research Fellow
North Bristol NHS Trust
anna.bibby@nbt.nhs.uk

Full Bio

Professor Biankin is a surgeon-scientist and Director of the Wolfson Wohl Cancer Research Centre at the University of Glasgow, where he established the Glasgow Precision Oncology Laboratory in 2016. Professor Biankin is also Chair of the UK-wide Precision-Panc programme of clinical trials for patients with pancreatic cancer. Professor Biankin is the Executive Director of the International Cancer Genome Consortium, Accelerating Research in Genomic Oncology (ICGC ARGO) project.
www.gpol.org

Prof Anne Willis

Director of the MRC Toxicology Unit
MRC Toxicology Unit, Cambridge
aew80@mrc-tox.cam.ac.uk

Full Bio

I am a social psychologist by background and have expertise in researching patient experience of symptoms, help-seeking, illness, and diagnosis. My research interests are in the areas of risk perception, risk communication, lived experience of disease, cancer early diagnosis, and promotion of early presentation with symptoms suggestive of cancer. I am interested in researching how patients make sense of their symptoms and seek medical help prior to receiving a mesothelioma diagnosis. I have recently worked on a project funded by the June Hancock Mesothelioma Research Fund which has focused on developing sustainable patient and public involvement (PPI) in mesothelioma research. I am looking for research collaborations that address or include psycho-social aspects of mesothelioma, e.g. patient experience of help-seeking for symptoms later diagnosed as mesothelioma; psychological adjustment to a diagnosis of mesothelioma; facilitating patient and carer involvement in mesothelioma research.

View Profile

Dr Avinash Aujayeb

Respiratory and Acute Medicine Consultant,  Northumbria HealthCare NHS Foundation Trust
Avinash.aujayeb@nhct.nhs.uk

Full Bio

Meso-ORIGINS study site PI for Northumbria Healthcare NHS Foundation Trust.
Avinash Aujayeb currently works as a Respiratory Medicine Consultant, Northumbria Healthcare NHS Foundation Trust. He is the Pleural Lead, a trustee for Mesothelioma UK, a member of the BTS Pleural SAG and Secretary for the Pleural and Mediastinal malignancies ERS group

Visit Profile

Prof Bruno Hochhegger

Pontifical Catholic University of Porto Alegre
Professor of Radiology
brunohochhegger@gmail.com

Full Bio
Reserch areas of interest:
Lung cancer
Malignancy
Magnetic resonance

Mrs Clare Orange

NRS GG&C Biorepository Manager
NHS Greater Glasgow & Clyde
clare.orange@ggc.scot.nhs.uk

Full Bio
As Biorepository Manager for NRS GG&C since 2019 I have a keen interest in supporting the application of human tissue in research and teaching. The Biorepository has delegated REC authority to provide surplus to diagnosis tissue to support academic, clinical and commercial research and also supports CTIMP and ATMP trials.
My interests and expertise also includes TMA construction, Digital Pathology and the development of AI in digital diagnostics.

Dr Christopher Craig

Respiratory Consultant
Manchester University NHS Foundation Trust
Christopher.craig@mft.nhs.uk

Full Bio
Meso-ORIGINS study site PI for Manchester University NHS Foundation Trust

Works as a Pleural and Lung Cancer Consultant working in a busy tertiary hospital.

Prof Colin Collins

Professor and Senior Scientist
University of British Columbia and the Vancouver Prostate Centre

Full Bio

Prof Collins has a B.Sc. in Biological Sciences from Western New England College, Springfield, MA, and a Ph.D. in Medical Genetics from the University of British Columbia. As a pioneer in the field of translational genomics, Prof Collins was deeply involved in the development of molecular cytogenetics. He was the first to establish that genome copy number alteration predicts the risk of metastasis in prostate cancer patients and pioneered paired-end sequencing and its application to genome mapping strategies. More recently, Prof Collins has helped elucidate the mechanisms of transdifferentiation from prostatic adenocarcinoma to lethal neuroendocrine cancer which led to the development of liquid biopsies for prostate cancer. He established that the tumour microenvironment participates in driving prostate cancer metastasis and identified, for the first time, therapeutic vulnerabilities of mesothelioma.

Dr Crispin Hiley

Associate Professor
UCL
crispin.hiley@ucl.ac.uk

Full Bio
Chief Investigator for HIT-MESO proton trial. Translation researcher at UCL Cancer Institute.

Dr Cyrus Daneshvar

Consultant Thoracic Medicine
University Hospitals Plymouth NHS Trust
cyrus.daneshvar@nhs.net

Full Bio
Meso-ORIGINS study site co-I for University Hospitals Plymouth NHS Trust
Interests: Malignant thoracic disease and interventional pulmonology

Prof Crispin Miller

Professor of Computational Biology
Beatson Institute for Cancer Research
Crispin.Miller@glasgow.ac.uk

Full Bio
PREDICT-Meso Co-Investigator WP1
The Miller group applies computational approaches including machine learning to the study of altered expression patterns in tumours. The group has a particular focus on the processes involved in the post-transcriptional regulation of protein expression

Prof Daniel Murphy

Professor of Lung Cancer & Mesothelioma
University of Glasgow
Daniel.Murphy@glasgow.ac.uk

Full Bio
PREDICT-Meso Co-Investigator- Lead WP3.2, Co-Lead WP4
Research interests: Genetically engineered mouse models of mesothelioma and pre-malignant disease; tumour: inflammation/immune cross-talk; oxidative stress; Hippo pathway

Prof David Chang

Professor of Surgical Oncology and Honorary Consultant Surgeon
University of Glasgow
david.chang@glasgow.ac.uk

Full Bio

David Chang is a surgeon scientist who specialises in the treatment of malignant pancreatic diseases. His research focus is on the development and implementation of novel therapeutic strategies for pancreatic cancer, particularly around DNA-damage response deficiency, by utilising molecular biomarkers of prognosis and therapeutic responsiveness. David co-leads Precision-Panc, a pan-UK initiative to deliver personalised cancer care for pancreatic cancer, and is the chief investigator of its Master Protocol and the first inter-related clinical trials. He is also involved in the Precision Promise initiative, a Pancreatic Cancer Action Network (USA) initiative dedicated in delivering personalized treatment for patients with pancreatic cancer, and contributes to ICGC ARGO, aiming to shape the future of the next generation cancer genomic projects to ultimately realise the goals and promises of precision medicine.

Clinically, David is an Honorary Consultant Pancreatic Surgeon at Glasgow Royal Infirmary as part of the West of Scotland Pancreatic Unit that serves as tertiary pancreatic referral centre for the West of Scotland. His research aims to shorten the distance between the bench and the clinic to ensure meaningful and seamless translation between the two.

Prof Hans-Ulrich Kauczor

Full Professor and Chairman of Radiology
University of Heidelberg

Full Bio
PREDICT-Meso Collaborator WP5.2
Full Professor and Chairman of Radiology (University of Heidelberg), Medical Director of Diagnostic and Interventional Radiology at the University Hospital Heidelberg, Acting head of the Department of Translational Pneumology. Research Interests: Imaging, CT, MRI; Functional imaging; Quantitative imaging biomarkers; Staging, response assessment, prognostication

Dr Glenn Masson

Principal Investigator
School of Medicine, University of Dundee
gmasson001@dundee.ac.uk

Full Bio

I am interested in the role of the Integrated Stress Response in the development of mesothelioma. I use a variety of biochemical, structural biological and drug discovery methods to investigate potential new routes to therapy.

www.masson-lab.com

Prof Jan van Meerbeeck

Professor of Thoracic Oncology
University of Antwerp
Jan.VanMeerbeeck@uza.be

Full Bio
PREDICT-Meso Co-Investigator WP5.1
Professor in Pulmonology at Antwerp University and chair of the Pulmonology Department of its academic hospital (UZA). His translational scientific interests include the molecular diagnosis of lung cancer, the management of mesothelioma and the evaluation of volatile biomarkers of asbestos exposure. Together with Kevin Lamote, he is the founder of the breathomics lab within the Laboratory of experimental medicine and pediatrics (LEMP) at University of Antwerp. Member of European Reference Network for rare/ low prelavent diseases (ERN-Lung); Senior consultant thoracic oncology; Honorary professor of pulmonology

Dr Janet Fallon

Consultant Respiratory Physician
Musgrove Park Hospital, Somerset NHS Foundation Trust
Janet.Fallon@SomersetFT.nhs.uk

Full Bio
Meso-ORIGINS study site PI for Somerset NHS Foundation Trust. I work as a general respiratory physician at a large district general hospital in Somerset, providing specialist services for our local population of 340,000 people. My interests include pleural disease, lung cancer diagnostics and interstitial lung disease. I play an active role in delivering clinical research and am currently PI for ASSES-meso and several other clinical trials at our centre.

Mr Joshua Roche

Predict-MESO PhD Student
University of Glasgow
j.roche.1@research.gla.ac.uk

Full Bio

Judy is a Professor in the Department of Cellular and Molecular Physiology at the University of Liverpool, where she runs a research group funded by North West Cancer Research, Breast Cancer Now, Fight for Sight, EPSRC and the NC3Rs. Her research interests are in deciphering the interplay between signalling, transcriptional regulation, and the modification of proteins by reversible ubiquitylation, with the aim of translating discoveries as potential therapeutic approaches or biomarkers, in mesothelioma, uveal melanoma or breast cancer. Her lab has been working on the discovery of BAP1-dependent therapeutic sensitivities in mesothelioma and recently developed novel chick embryo CAM xenografts of mesothelioma cell lines and patient-derived tissues (PDX) for preclinical testing. Judy has established a Liverpool Chick Embryo Facility (CEF) together with the Facility Manager Dr Sarah Barnett at the University of Liverpool, which can provide collaborative support or services for internal and external projects. Judy is a member of the Mesothelioma UK Research and Audit Scientific Committee and has served on advisory boards including the Mesothelioma Research Network Steering Group. She is the Deputy Associate Pro Vice Chancellor for Technology, Infrastructure and Environment in the Faculty of Health and Life Sciences at Liverpool, and the Faculty Lead for Equality Diversity and Inclusion.

 

View Profile

Prof John Le Quesne

Professor in Molecular Pathology
Beatson Institute for Cancer Research
John.LeQuesne@glasgow.ac.uk

Full Bio
PREDICT-Meso Collaborator WP1&2

The Le Quesne group use quantitative deep phenotyping methods to ask questions about tumour biology in intact tissues from humans and from animal models. We have particular interests in the dysregulation of mRNA translation, in the complex tumour microenvironment, in morphological biomarkers, and in the development of highly multiplexed quantitative methods using machine learning methods. Mesothelioma is an area of particular interest.

Dr John Maclay

Consultant in Respiratory Medicine, Honorary Clinical Senior Lecturer and NRS Career Research Fellow,
Glasgow Royal Infirmary- NHSGGC
john.maclay@ggc.scot.nhs.uk

Full Bio
Meso-ORIGINS study site PI for Glasgow Royal Infirmary (GRI), NHS Greater Glasgow and Clyde. Dr Maclay is a consultant respiratory physician based at GRI with a specialist interest in lung cancer. He was awarded an NRS fellowship in 2020, allowing him to pursue his research interests.

Prof Judy M Coulson

Professor
University of Liverpool
jcoulson@liverpool.ac.uk

Full Bio

Judy is a Professor in the Department of Cellular and Molecular Physiology at the University of Liverpool, where she runs a research group funded by North West Cancer Research, Breast Cancer Now, Fight for Sight, EPSRC and the NC3Rs. Her research interests are in deciphering the interplay between signalling, transcriptional regulation, and the modification of proteins by reversible ubiquitylation, with the aim of translating discoveries as potential therapeutic approaches or biomarkers, in mesothelioma, uveal melanoma or breast cancer. Her lab has been working on the discovery of BAP1-dependent therapeutic sensitivities in mesothelioma and recently developed novel chick embryo CAM xenografts of mesothelioma cell lines and patient-derived tissues (PDX) for preclinical testing. Judy has established a Liverpool Chick Embryo Facility (CEF) together with the Facility Manager Dr Sarah Barnett at the University of Liverpool, which can provide collaborative support or services for internal and external projects. Judy is a member of the Mesothelioma UK Research and Audit Scientific Committee and has served on advisory boards including the Mesothelioma Research Network Steering Group. She is the Deputy Associate Pro Vice Chancellor for Technology, Infrastructure and Environment in the Faculty of Health and Life Sciences at Liverpool, and the Faculty Lead for Equality Diversity and Inclusion.

 

View Profile

Dr Kevin Lamote

Collaborator WP5.1, lead for Meso-ORIGINS study exhaled breath analysis
Postdoc researcher, University of Antwerp
Kevin.Lamote@uantwerpen.be

Full Bio

PREDICT-Meso Collaborator WP5.1, lead for Meso-ORIGINS study exhaled breath analysis

Kevin Lamote graduated as Master in Biomedical Sciences in 2011 at Ghent University (Belgium). At the same university, he obtained his PhD in 2017 where he developed and validated a breath test to detect malignant pleural mesothelioma and lung cancer in at risk asbestos-exposed individuals based upon the analysis of volatiles in breath by using mass spectrometry, sensor and spectroscopic techniques. Since then, he works as postdoc at the University of Antwerp where he is currently assessing the clinical utility of the breath test and extending his research to studying the volatiles in the gut and lung microbiome, and their use as diagnostic and monitoring biomarkers in non-malignant diseases in vivo as well as in vitro. He is a member of the European Respiratory Society and the international Association for breath research. He is also associate editor for Microbiota in Health and Disease and a member of the Basic Science Working Group of the Belgian Respiratory Society. He is (co-)promotor of 6 ongoing PhD’s all studying different aspects of breath analysis.

View Profile

Prof Kevin Blyth

Professor of Respiratory Medicine
University of Glasgow
Kevin.Blyth@glasgow.ac.uk

Full Bio

PREDICT-Meso Network PI, Co-Lead WP1, Co-Lead WP5.1

Kevin Blyth is Professor of Respiratory Medicine at University of Glasgow, and Honorary Consultant in Respiratory Medicine at NHS Greater Glasgow and Clyde (NHSGGC). Following completion of Internal and Respiratory Medicine training and the award of an MD in Magnetic Resonance Imaging, he was appointed as a Consultant in 2009. He splits his time between the CRUK Beatson Institute/University of Glasgow and the Queen Elizabeth University Hospital, where he leads the Glasgow Pleural Disease Unit. He founded and is Director of the Macmillan Scottish Mesothelioma Network, which coordinates clinical care and access to clinical trials for Mesothelioma patients in Scotland. He is an NHS Scotland Research (NRS) Senior Research Fellow and leads a translational research program focused on pleural disease and thoracic malignancy, and has a particular interest in Mesothelioma. He is Principal Investigator of the CRUK PREDICT-Meso International Accelerator Network, and Meso-ORIGINS study site PI for the Queen Elizabeth University Hospital, NHS GGC.

View Profile

Dr Klaus Irion

Manchester University NHS Foundation Trust
Klaus.Irion@mft.nhs.uk

Full Bio

PREDICT-Meso Co-Investigator WP5.1

Research Interests: Lung Cancer Imaging, COPD Diffuse Interstitial Lung Diseases, Imaging Quantification, Medical Education

Dr Luciano Mutti

Professor Translational Oncology
SHRO/Temple University, Philadelphia, USA
luciano.mutti@temple.edu

Full Bio

I have been working on mesothelioma (MPM) for many years and published 113 peer reviewed papers on this tumor to date. My group is currently particularly active in setting up 3D model of MPM and Bio-banking aimed at validating novel avenues of treatment. We have developed an extended expertise in detecting novel actionable targets with particular focus in DNA repair, metabolism and markers of immune-resistance

 

Prof Luisella Righi

University of Turin
Associate Professor of Pathology

Full Bio
PREDICT-Meso Collaborator WP1

Full Bio
As a pathologist I’m daily dedicated to diagnostic histopathology and cytology of thoracic oncology together with diagnostic immunohistochemistry and molecular biology techniques applied to histo- and cytopathology. As a researcher my fields of interest are mainly focused on translational studies of histology, immunohistochemistry and molecular pathology applied to thoracic tumors: in particular, I studied the application of immunocytochemistry and molecular biology to identify new biomarkers of neoplasia and/or characterise the phenotypic and molecular profile of various human thoracic tumors, such as non-small cell lung cancer, malignant pleural mesothelioma and neuroendocrine tumors, establishing correlation with clinico-pathological parameters, response to therapy and prognosis.
Prof Righi’s team will provide retrospective MPM pairs and provide expertise in diagnostic histo- and cyto-pathology on MPM samples as part of WP1 .

Dr Lucy Jackson Jones

Lecturer in Biomedicine
Lancaster University
L.jackson-jones@lancaster.ac.uk

Full Bio

The Jackson-Jones group focuses on local immune responses occurring within the body cavities. We investigate the interaction between fat associated lymphoid clusters and their products (antibodies/lipids/cytokines) with immune cells within the peritoneal and pleural fluid in the context of inflammation, infection and cancer.

Visit Profile

Dr Mahendran Chetty

Consultant Respiratory Physician
NHS Grampian
mahendran.chetty@nhs.scot
 

Full Bio

Areas of interest: Pleural disorders and interventions, lung cancer including mesothelioma endobronchial ultrasound
Clinical lead for Pleural diseases
Clinical lead Scottish National Mesothelioma Network – Grampian

Visit page

Dr Manel Esteller

Director
Josep Carreras Leukaemia Research Institute (IJC)
mesteller@carrerasresearch.org

Full Bio
PREDICT-Meso Co-Investigator WP2

The Cancer Epigenetics group continues the wide-ranging work on epigenetics that Manel Esteller, the group leader, has carried out during his career until now. Current research is devoted to the establishment of the epigenome and epitranscriptome maps for normal and transformed cells, the study of the interactions between epigenetic modifications and non-coding RNAs, and the development of new epigenetic drugs for cancer therapy.
The Cancer Epigenetics Group’s main research interests are:
– Epigenetic disruption of mRNA transcription, particularly in DNA methylation and histone modification patterns, and its contribution to the initiation and progression of human tumours.
– Translation of the use of epigenetic knowledge gained from research into biomarkers to predict clinical outcome and to assay new drugs to reverse the distorted epigenetic landscape.
– Development and study of new epigenetic drugs that target DNA methylation and histone modification writers, readers and erasers and could have an anti-cancer effect.
– Study of monogenic disorders affecting epigenetic genes, particularly in Rett syndrome.
Study of epigenomic profiles of common diseases such as cardiovascular alterations and Alzheimer and other neurodegenerative diseases.
– Establishment of new epigenomic platforms to elaborate comprehensive DNA methylome maps.
In addition, the study of epitranscriptomics is a focus of intense research in the group.

Dr Marion MacFarlane

Deputy Director of the MRC Toxicology Unit
University of Cambridge
mm2312@mrc-tox.cam.ac.uk

Full Bio

PREDICT-Meso Co-Investigator- Co-Lead WP3.1, Co-Lead WP4

Full Bio
Prof. MacFarlane co-leads the ‘Mechanisms of Fibre Toxicity’ Programme at the MRC Toxicology Unit. The MRC team have characterised asbestos-induced mesothelioma development in vivo via longitudinal analysis of candidate tumour suppressor gene status throughout disease development in the pleura (Chernova et al, Curr Biol 2017). In addition, the team have successfully established low-passage patient-derived mesothelioma cell lines (PDCLs) from surgical resections, and have shown these recapitulate human disease (Chernova et al, Cell Death Differ 2016). The team will contribute to PREDICT-Meso by 1) establishing well-characterised PDCLs from pleural effusions, obtained at both pre-MPM and MPM stage (WP3), 2) in collaboration with the Bianchi team (Milan), establish 3D organotypic models for initial in vitro validation of drug screen candidates/target-drug validation (WP3&4), and 3) with the Murphy Lab (Glasgow), help establish and subsequently employ immunocompetent GEM models of asbestos-induced pleural mesothelioma for target-drug validation in vivo (WP4)

 

View Profile

Prof Marco Bianchi

Professor
Università Vita-Salute San Raffaele (UniSR), Milan
bianchi.marco@hsr.it

Full Bio

PREDICT-Meso Co-Lead WP3.1, Co-Investigator WP4

My group participated in the identification of HMGB1 as an initial pathogenetic trigger in the inflammation that accompanies the development of mesothelioma and later as a pro-tumoral molecule secreted by tumour cells and macrophages in mesothelioma.
More recently, we have been developing molecules to target, mouse models of mesothelioma and organoids from human mesothelioma fragments to assess the efficacy of antitumor drugs.
We have recently developed technology to obtain organoids from human and mouse non-tumoral pleura and mesothelioma surgical fragments and will disseminate to other coinvestigators in the UK our expertise in generating and exploiting these novel patient-derived models (as part of WP3). As part of WP4, we also plan to test BoxA, our most interesting anti-mesothelioma drug lead, as an exemplar drug on human organoids and on genetically modified mesothelioma models (GEMMs) developed by other team members

View Profile

Dr Mark Neilly

Clinical Research Fellow
University of Glasgow
mark.neilly@ggc.scot.nhs.uk

Full Bio
Meso-ORIGINS – Clinical Study Coordinator

Mark Neilly graduated with an MBChB from the University of Dundee in 2016 and completed Internal Medicine Training in the West of Scotland in 2022.

He is currently undertaking a PhD in Cancer Sciences with the University of Glasgow.
His role is centred around the clinical elements of PREDICT-Meso, namely the coordination of recruitment to Meso-ORIGINS.

Dr Matheus Zanon

PREDICT-Meso PhD Student
St. Lucas Hospital, Pontifical Catholic University of Rio Grande do Sul, Brazil
m.zanon22@edu.pucrs.br

Full Bio

Medical Degree by the Federal University of Health Sciences of Porto Alegre (UFCSPA), in Porto Alegre, Brazil.
MSc in Investigative Pathology at UFCSPA.
PhD student in Investigative Pathology at UFCSPA.
Radiology resident at St. Lucas Hospital, Pontifical Catholic University of Rio Grande do Sul, Brazil
Special research interests in thoracic imaging, quantitative analysis of imaging exams, and meta-analyses.

Visit Page

Prof Mauro Papotti

Head of the Pathology Unit
University of Turin at Health and Science City Hospital
mauro.papotti@unito.it

Full Bio
PREDICT-Meso Collaborator WP1

Prof Papotti’s team will provide retrospective MPM pairs and provide expertise in diagnostic histo- and cyto-pathology on MPM samples as part of WP1.

Dr Matthew Evison

Consultant Chest Physician
Manchester University NHS Foundation Trust
matthew.evison@mft.nhs.uk

Full Bio

PREDICT-Meso Co-Investigator WP1

Consultant Chest Physician at Wythenshawe Hospital, Manchester University NHS Foundation Trust.

Clinical lead for the CURE programme and Tobacco Addiction and a core member of the Specialist Lung Cancer and Pleural Teams. This role includes delivery of the CURE, RAPID and Lung Health Check programmes at Wythenshawe Hospital.

Director of the Lung Pathway Board and clinical lead for the CURE project for Greater Manchester.

Member of the British Thoracic Society Specialist Advisory Groups for Tobacco and Pleural and a member of the British Thoracic Oncology Group Steering Committee.

Prof Michelangelo Campanella

Professor of Pharmacology
Royal Veterinary College, University of London
mcampanella@rvc.ac.uk

Full Bio

Prof. Campanella is internationally acknowledged as an expert in the field of mitochondrial cell biology and pharmacology. His scientific breakthroughs, up to date, regard hidden pathways of homeostatic mitochondrial function and their pharmacological regulation. As leader of the RVC oncology interest group he is engaged in studying Malignant Pleural Mesothelioma (MPM) pathogenic signalling for which they have developed useful tools of analysis, and gained valuable observations on regulatory mechanisms of intracellular communication. The overall aim is to unveil early predictive markers as well as targets for therapeutic intervention to be achieved by pursuing comparative validation approaches.

Visit Profile

Dr Melissa LaBonte Wilson

Lecturer, Patrick G Johnston Centre for Cancer Research
Queen’s University Belfast
m.labontewilson@qub.ac.uk

Full Bio

Recent research has highlighted a novel and transformative therapeutic opportunity that improves the efficacy of chemotherapies that target the enzyme thymidylate synthase (TS). This includes chemotherapies used in mesothelioma such as pemetrexed and raltitrexed. The enzyme TS is critical for the synthesis of thymidylate (dTMP), an essential precursor for production of thymine (dTTP) for DNA. During treatment with TS-targeted chemotherapy, cancer cells are rapidly depleted of dTTP, stalling cancer cell growth. Recently, it was discovered that co-targeting the uracil-DNA misincorporation pathway improves response to TS-targeted therapies and our work seeks to characterize this and develop novel-combination therapies to improve current standard chemotherapies for mesothelioma.

Prof Najib Rahman

Professor of Respiratory Medicine and Director
Oxford Respiratory Trials Unit
najib.rahman@ouh.nhs.uk

Full Bio
PREDICT-Meso Collaborator WP1

Providing expertise in clinical trials, translational mesothelioma work including cell lines and drug sensitivity. Meso-ORIGINS study site PI for Manchester University NHS Foundation Trust.

Dr Nikolaos Kanellakis

Postdoctoral Researcher
Nuffield Department of Medicine, Medical Sciences Division, University of Oxford
nikolaos.kanellakis@ndm.ox.ac.uk

Full Bio

Nikolaos is the lead postdoctoral researcher at the laboratory of Pleural and Lung Cancer Translational Research, Nuffield Department, University of Oxford. His interests are focused on the development of faithful models of pleural disease which could be applied in translational research.

Visit Profile

Prof Nick Maskell

Professor of Respiratory Medicine
North Bristol NHS Trust
nick.maskell@bristol.ac.uk

Full Bio
PREDICT-Meso Co-Investigator WP1

Research interests: Randomised controlled clinical trials; Pleural disease & interventions; Newer treatments including immunotherapy

Dr Rakesh K Panchal

Consultant Respiratory Physician
Glenfield Hospital, University Hospitals of Leicester NHS Trust
rakesh.panchal@uhl-tr.nhs.uk

Full Bio
Meso-ORIGINS study site PI for University Hospitals of Leicester NHS Trust.
Interests: Pleural diseases – mesothelioma, pleural effusions, pneumothorax, pleural infection/empyema
Interventional pulmonology – thoracoscopy, IPCs, EBUS, bronchoscopy, endobronchial valves, cryobiopsy

Dr Olivier E Pardo

Senior Lecturer/ Team Leader
Division of Cancer/Department of Surgery and Cancer/Imperial College
o.pardo@imperial.ac.uk

Full Bio

My lab is specialised in understanding how changes in cellular signalling modulates drug resistance and metastasis in cancer. Our research in mesothelioma focusses on the signalling crosstalk between tumour cells and cancer-associated fibroblasts and its role in disease progression. We identified several molecular mediators of this crosstalk and demonstrated that targeting them provides superior inhibition of mesothelioma growth than current standard-of-care. We are now testing several targeted therapeutic combinations in vivo with the long-term hope of translating our findings into novel therapies for mesothelioma patients.

visit profile

 

Dr Phil Reid

Consultant in Respiratory and General Medicine
Western General Hospital, NHS Lothian
Phil.Reid@nhslothian.scot.nhs.uk

Full Bio
I have been a consultant in respiratory medicine at WGH since 2014 with sub specialty interest in lung cancer and pleural disease. I served as clinical lead for the department between 2018 and 2022. In 2018 I was appointed lead for mesothelioma in South East Scotland as part of the Scottish mesothelioma network and was also appointed lung cancer lead in Lothian from 2022.

Dr Philip Short

Consultant Physician
Ninewells Hospital Dundee, NHS Tayside
philip.short@nhs.scot

Full Bio
Honorary Senior Lecturer (University of Dundee)
Macmillan Mesothelioma Lead Clinician NHS Tayside

Prof Robert Jones

Professor of Clinical Cancer Research
CRUK Glasgow Clinical Trials Unit

Full Bio
PREDICT-Meso Co-Investigator WP1
Cancer Clinical Trials Unit Director. The CRUK Glasgow CTU runs a comprehensive service to design, implement, run and analyse cancer clinical trials

Dr Robert Rintoul

University Reader in Thoracic Oncology
University of Cambridge
Robert.rintoul@nhs.net

Full Bio

PREDICT-Meso Co-Investigator & Co-Lead WP1

Dr Rintoul is University Reader in Thoracic Oncology in the Department of Oncology, University of Cambridge and Honorary Consultant Respiratory Physician, Royal Papworth Hospital. He trained in respiratory medicine in London and Edinburgh receiving his doctorate from the University of Edinburgh for work investigating mechanisms underlying resistance to chemotherapy in small cell lung cancer. He was appointed consultant in respiratory medicine specialising in thoracic oncology at Royal Papworth Hospital in 2005 before taking up his current post in 2017. Dr Rintoul is lead clinician for cancer at Royal Papworth Hospital and Director of the Papworth Trials Unit Collaboration. He is co-lead of the CRUK Cambridge Centre Aerodigestive Programme and co-ordinates thoracic oncology research across Cambridge. From January 2021 he has been appointed chair of the clinical advisory group of the UK Lung Cancer Coalition.

Dr Rintoul’s research is focused around clinical trials, translational research and tissue banking in malignant mesothelioma and the early detection of lung cancer. He is Chief Investigator for several clinical translational studies examining biomarkers in lung cancer. In 2012 he founded MesobanK, the UK national bioresource for malignant mesothelioma (www.mesobank.com). His work is funded by the Cambridge Biomedical Research Centre, Cancer Research UK, National Institute for Health Research and the British Lung Foundation. He is Co-Lead for PREDICT-Meso WP1 and Meso-ORIGINS study site PI for Royal Papworth Hospital.

View Profile

Prof Sam Janes

Professor of Respiratory Medicine
University College London (UCL)
s.janes@ucl.ac.uk

Full Bio
PREDICT-Meso Lead WP3.3 and Co-Investigator WP4

Sam won an MRC Training Fellowship to perform a PhD and then a post-doctoral period working in the CRUK Lincoln’s Inn Fields Institute with Fiona Watt working on stem cell biology. He then moved as an MRC Clinician Scientist to UCL leading a group interested in the role of stem cells in lung cancer pathogenesis and treatment of lung disease using cell therapies. He was awarded a Wellcome Trust Senior Clinical Fellowship in October 2010 to work on novel cell therapies for lung cancers resulting in a DPFS first-in-man award and in 2015 won his Wellcome Senior Fellowship renewal to study the genetic and cellular changes lung cancer pathogenesis. He is the lead of four academic randomised clinical trials and most notably recently launched the SUMMIT study, a 25,000 participant London based study examining CT and blood screening for lung and other cancers.
He works as a respiratory consultant at UCLH with a particular interest in lung cancer, mesothelioma, interventional and diagnostic bronchoscopy and early lung cancer detection. He is Head of Respiratory Research Department at UCL, Vice-Chair of the National ‘Clinical Expert Group’ on Lung Cancer.

Dr Selina Tsim

Consultant Respiratory Physician
Queen Elizabeth Unviersity Hospital, Glasgow
Selina.Tsim@ggc.scot.nhs.uk

Full Bio
Meso-ORIGINS study site PI for Gartnavel General Hospital, NHS Greater Glasgow and Clyde. Selina Tsim is a consultant chest physician with a specialist interest in mesothelioma. She is a clinical lead for the Macmillan Scottish Mesothelioma Network and an honorary clinical senior lecturer at the Institute of Cancer Sciences, University of Glasgow. She is a co-author of the most recent British Thoracic Society Guidelines for the Investigation and Management of Malignant Pleural Mesothelioma. In 2020 she was awarded an NHS Research Scotland Career Research Fellowship.

Dr Seth Coffelt

Senior Research Fellow
University of Glasgow
Seth.Coffelt@glasgow.ac.uk

Full Bio
PREDICT-Meso Co-Investigator WP2.4
The Coffelt lab is a cancer immunology lab focused on immune escape and immunosuppression in mouse models of cancer. They are particularly interested in gamma delta-cells, a T-cell receptor-expressing immune cell population with innate-like characteristics.

Dr Stéphane LeBihan

Manager, Genomics core
Vancouver Prostate Centre
slebihan@prostatecentre.com

Full Bio

As a manager of a genomics core, I have a strong interest in using cutting-edge technology to understand and manipulate genetic information. I am passionate about the potential of genomics to revolutionize healthcare and the life sciences, and I enjoy the challenge of coordinating the work of a team of scientists and technicians to achieve this goal. I like managing complex projects, overseeing budgets and schedules, and communicating effectively with stakeholders. My ultimate goal is to lead the facility to make breakthroughs that improve human health and well-being.

Visit Page

Dr Stephan Altmayer

Radiology Resident
Stanford University
altmayer@stanford.edu

Full Bio

I am interested in the application of CT and MRI in cardiothoracic imaging.

Visit Page

Dr Susana Cedres

Medical oncologist
Vall d’Hebron Institute of Oncology (VHIO)
scedres@vhio.net

Full Bio
PREDICT-Meso Co-Investigator – Lead WP2

Dr. Cedrés graduated in Medical Oncology in 2005 by Hospital Universitario de Canarias. Since 2005 she has been working at the thoracic tumors unit at Vall d´Hebron University hospital with attention to investigation in clinical trials in lung cancer and mesothelioma patients.
In 2014 she obtained her PhD by Universidad Autonoma de Barcelona working in expression of PD-L1 in malignant pleural mesothelioma patients. She has publications about prognostic and predictive markers of response in thoracic tumors. Currently she is specialized in the investigation of biomarkers of response to therapies in thoracic tumors and she participates in the development of new drugs for these patients.

Dr Timothy Gatheral

Clinical Lead for Respiratory Medicine
University Hospitals of Morecambe Bay NHS Foundation Trust
timothy.gatheral@mht.nhs.uk

Full Bio

Dr Gatheral studied medicine at Cambridge University and completed his PhD in cardiothoracic pharmacology at Imperial College London in 2012. After completing a year as an NIHR clinical lecturer he took up a post as a consultant respiratory physician at University Hospitals of Morecambe Bay. Since 2014 he has built up the Interstitial Lung Disease Service across Morecambe Bay and works in the North Lancashire/South Cumbria Interstitial Lung disease specialist network. In addition he is secondary care lead for the integrated Morecambe Bay Respiratory Network (MBRN) and actively participates in clinical research studies at the Trust. He combines his clinical work with a role as senior clinical lecturer at Lancaster University Medical School.

Mrs Victoria Thomas

Research Nurse
Salford Royal Hospital
vicky.thomas@nca.nhs.uk

Full Bio

I am a Research Nurse at Salford Royal and I am proud to be the lead nurse for Meso-ORIGINS Study site Salford. I have been working as a Research Nurse since 2015 and in that time I have worked on many interesting studies in different specialties.
Oncology (2015-2018 STAMPEDE/RADICALS/PATCH) Core Research Team ( 2018-2020 100K GENOMES, SUNRRISE STUDY, CIPHER, PURE,FUTURE) Covid Research Team (2020-2022 RECOVERY,REMAP-CAP, GENOMICS,ISARIC, COVID VACCINATIONs)
Acute Research Team/Inpatient Research Team (2022-present SCIL, HEMOTION, REMAP-CAP, DISCUS, PQIP, ROSA IBD trials intestinal failure – STARS, EASE).

Ms Taylla Milena Theodoro

Student of M.Sc in Computer Science
Laboratory of Image Data Science (LIDS), Institute of Computing (IC) , University of Campinas
taylla.theodoro@students.ic.unicamp.br

Full Bio

Master’s student in Computer Science (2021-2023) at the Institute of Computing at the State University of Campinas (UNICAMP), supervised by Professor Alexandre Xavier Falcão, developing the work entitled “Towards Detection of Malignant Mesothelioma from 4D Magnetic Resonance Images of the Thorax” in the area of Medical Image Processing, with the financial support of a FAPESP scholarship, at the LIDS (Laboratory of Image Data Science) research laboratory. Bachelor of Electrical Engineering from the State University of Londrina (2016-2020).

Visit Page